Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Carsgen Therapeutics Holdings Ltd.
Industry Sector: HealthTechnology
CEO: Zong Hai Li, MD, PhD
Number Of Employees: 516
Enterprise Value: $214,078,510
PE Ratio: -9.58
Exchange/Ticker 1: HKEX:2171
Exchange/Ticker 2: N/A
Latest Market Cap: $936,887,087
BioCentury | Jan 4, 2025
Management Tracks
Four companies announce new CFOs
Plus: Jia joins Grit Bio and Riley joins Avalo
BioCentury | May 24, 2024
Product Development
Clinical Report: Merus data stand out among ASCO highlights
Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
BioCentury | Apr 2, 2024
Data Byte
With Astellas’ Vyloy, GI tumor target CLDN18.2 gets first approval
At least 32 other programs targeting CLDN18.2, spanning six modalities, are in clinical testing for gastrointestinal tumors
BioCentury | Dec 14, 2023
Deals
Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal
Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
BioCentury | Oct 21, 2023
Management Tracks
Daly to succeed McEnany as Catalyst CEO
Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell
BioCentury | Sep 11, 2023
Deals
Sept. 11 Quick Takes: Surprise miss for Acelyrin in hidradenitis suppurativa
Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé
BioCentury | Sep 9, 2023
Deals
CAR T collaborations: the next cross-border deal trend?
BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
BioCentury | Aug 22, 2023
Regulation
Aug. 21 Quick Takes: Pfizer’s Abrysvo granted maternal indication
Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more
BioCentury | Feb 28, 2023
Data Byte
AZ enters crowded CLDN18.2 clinical race via Keymed deal
At least 28 therapies targeting CLDN18.2 have started clinical trials for cancer
BioCentury | Jan 18, 2023
Regulation
Jan. 17 Quick Takes: Moderna now in RSV vaccine regulatory race
Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more
Items per page:
1 - 10 of 18